MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'cancer network'. Sat, 03 Sep 2011 02:57:23 +0100 http://www.medworm.com/index.php?rid=5069826&cid=t_406388_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F51VWUJEh5j8%2F Earlier this month, the National Comprehensive Cancer Network, a non-profit group of oncologists whose guidance is closely followed by leading treatment centers, voted overwhelmingly in favor of maintaining its recommendation that Avastin should be used to treat breast cancer. The vote came shortly after an FDA panel voted 6-to-0 to revoke the breast cancer indication for Avastin. The endorsement is important because oncologists will likely continue to use Avastin even if FDA commish Margaret Hamburg rescinds the breast cancer indication. Roche and its Genentech unit had appealed a decision last December by the agency to pull the indication for their best-selling med after new studies showed Avastin does not prolong overall survival in breast cancer patients or provide a sufficient benefi... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=5069826 Tue, 26 Jul 2011 13:24:27 +0100 5069826 http://www.medworm.com/index.php?rid=4331237&cid=t_406388_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FibJkV92R2cc%2F In a move that will hearten breast-cancer patients, several large insurers will continue to cover the Avastin medication, even though the FDA is taking steps to remove that indication for the Roche drug. The agency is doing so after analyzing clinical studies that found Avastin does not prolong overall survival or provide a sufficient benefit in slowing disease progression to outweigh serious side effects (back story). Among the insurers are UnitedHealth and WellPoint, which have cited a recommendation by the National Comprehensive Cancer Network, a non-profit group of oncologists whose guidance is closely followed. However, eight of the 33 members on its breast cancer panel have various ties to Roche and its Genentech unit as advisory board members, speakers, consultants, expert witnesses... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4331237 Tue, 11 Jan 2011 13:26:25 +0100 4331237 http://www.medworm.com/index.php?rid=4314191&cid=t_406388_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F01%2F05%2Fnational-comprehensive-cancer-network%25c2%25ae-posts-new-guidelines-for-treatment-of-ovarian-cancer-patients%2F National Comprehensive Cancer Network® Posts New “Patient Friendly” Guidelines for Treatment of Ovarian Cancer. Women with ovarian cancer now have a new resource that provides them with the same credible information their physicians use when determining treatment options. The National Comprehensive Cancer Network® (NCCN®) announces three new additions to the library of NCCN Guidelines for [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4314191 Wed, 05 Jan 2011 19:39:13 +0100 4314191 http://www.medworm.com/index.php?rid=3718697&cid=t_406388_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FlMT1GNwF2yc%2F Last night, the latest chapter in the Provenge saga was unexpectedly written - the news that the Centers for Medicare & Medicaid Services was reviewing coverage for the Provenge prostate cancer vaccine sent Dendreon shares plunging as much as 23 percent in after-hours trading. Coupled with manufacturing constraints that are causing rationing, investors were caught off guard. That’s because a National Coverage Determination usually isn’t issued for cancer treatments. In fact, an NCD is uncommon for new drugs, in general. What likely prompted this move were requests from local Medicare providers, or what RW Baird analyst Chris Raymond calls “local fiscal intermediaries.” Why? Remember that Provenge is unusual in that it works by stimulating a patient’s own ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3718697 Thu, 01 Jul 2010 12:36:12 +0100 3718697 http://www.medworm.com/index.php?rid=3563958&cid=t_406388_87_f&fid=38368&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FDisruptiveWomenInHealthCare%2F%7E3%2FUHjGKILo-L8%2F By Archelle Georgiou. On Wednesday, the FDA suddenly decided to impose their regulatory authority on personalized genetic test kits after Walgreens and Pathway Genomics announced they’d be selling them in local pharmacies. But, what triggered this response from the FDA? Are they new? No. These kits have been available to consumers via the Web for 3 years. Have they been off the regulatory radar screen? No. As far back as 2008, the rapid emergence of genetic testing fueled the passage of GINA, a federal law prohibiting health insurers and employers from discriminating on the basis of genetic information. Have these companies been quietly launching their strategy and staying invisible? No. They have made major investments in marketing with an abundant amount of media coverage in women&... Disruptive Women in Health Care blogs http://www.medworm.com/rss/comments.php?id=3563958 Fri, 14 May 2010 11:57:24 +0100 3563958 http://www.medworm.com/index.php?rid=3212566&cid=t_406388_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F01%2F26%2Ftwo-combination-treatment-regimens-added-to-updated-nccn-guidelines-for-ovarian-cancer%2F The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Ovarian Cancer to include two additional combination treatment regimens for women with select types of recurring ovarian cancer. The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology™ for Ovarian Cancer to reflect the addition of two preferred combination [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3212566 Wed, 27 Jan 2010 04:44:49 +0100 3212566 http://www.medworm.com/index.php?rid=2716192&cid=t_406388_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F08%2F19%2Fnccn-updates-infection-guidelines-to-include-information-about-h1n1-virus-swine-flu%2F NCCN [National Comprehensive Cancer Network] recently updated the NCCN Clinical Practice Guidelines in Oncology™ for the Prevention and Treatment of Cancer-Related Infections to include information about the H1N1 virus, also known as “swine flu”. The NCCN Guidelines provide specific recommendations on the prevention, diagnosis, and treatment of the major common and opportunistic infections that afflict [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2716192 Wed, 19 Aug 2009 21:08:06 +0100 2716192 http://www.medworm.com/index.php?rid=1516779&cid=t_406388_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F311280258%2F In response to criticism, the National Comprehensive Cancer Network, which is an alliance of 21 leading cancer centers, has decided to expand its disclosure policy and make public all potential conflicts of interest of all individual expert panel members by the end of 2008. The move, which was made last week, followed complaints that the NCCN’s Drugs and Biologics Compendium for failing to disclose corporate ties of the 20 to 24 experts who sit on 44 guideline-writing panels. Instead, the NCCN listed all companies that gave money or research support to any committee member without listing any specific member or the amount given. The compendium may be used by Medicare to justify reimbursement for off-label use of cancer drugs. Historically, the NCCN has disclosed the names of companie... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1516779 Fri, 13 Jun 2008 17:13:02 +0100 1516779 http://www.medworm.com/index.php?rid=1451974&cid=t_406388_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F293531036%2F Medicare is nearing approval of three additional drug compendia that can be used to justify reimbursement for off-label use of cancer drugs, including one that violates agency guidelines on conflict-of-interest disclosure, according to Integrity in Science Watch. The National Comprehensive Cancer Network’s Drugs and Biologics Compendium, which is drawn from its Clinical Practice Guidelines, fails to disclose corporate ties of the 20 to 24 experts who sit on its 44 guideline-writing panels. Instead, it lists all the companies which gave money or research support to any committee member without listing any specific member or the amount given, ISW writes. In 2006, the Medicare Evidence Development and Coverage Advisory Committee recommended that any new compendia approved by the Center for ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1451974 Mon, 19 May 2008 14:13:06 +0100 1451974